TY - JOUR
T1 - Sleep medication use and incident dementia in a nationally representative sample of older adults in the US
AU - Robbins, Rebecca
AU - DiClemente, Ralph J.
AU - Troxel, Andrea B.
AU - Jean-Louis, Girardin
AU - Butler, Mark
AU - Rapoport, David M.
AU - Czeisler, Charles A.
N1 - Funding Information:
In conclusion, high quality geriatric care must be a top priority with an aging population, as noted by the Institute of Medicine [42]. Our findings provide further support and evidence that sleep medications are all too commonly administered, yet associated with greater risk for incident dementia, and that the US healthcare system is in need of creative solutions for addressing poor sleep among older individuals.This work was supported by awards K01HL150339, U54MD000538, K07AG052685, R01AG056531, R01AG056031.Dr. Rapoport has received consulting fees from Jazz Pharmaceuticals, Eight Mattress, and Fischer and Paykel Healthcare. Dr. Robbins has received consulting fees from Denihan Hospitality, Rituals Cosmetics, Sleep Cycle, and by Nacht. Dr. Czeisler reports grants from Mary Ann & Stanley Snider via Combined Jewish Philanthropies, grants from National Football League Charities, grants from Optum, grants from Philips Respironics Inc, grants from ResMed Foundation, grants from San Francisco Bar Pilots, other from Schneider Inc, grants from Sysco Corp, grants from Teva Pharmaceuticals Industries Ltd, personal fees from Bose Corporation, non-financial support from Boston Celtics, personal fees from Boston Red Sox, personal fees from Columbia River Bar Pilots, personal fees from Institute of Digital Media and Child Development, personal fees from Klarman Family Foundation, personal fees from Samsung Electronics, personal fees and other from Vanda Pharmaceuticals Inc, personal fees from Zurich Insurance Company Ltd, personal fees from McGraw Hill, other from Cephalon Inc, personal fees from Washington State Board of Pilotage Commissioners, personal fees from Ganésco Inc, grants from Jazz Pharmaceuticals Plc Inc, grants from Regeneron Pharmaceuticals, grants from Sanofi SA, personal fees from New England Journal of Medicine, personal fees from Teva Pharma Australia, personal fees from AARP, personal fees from American Academy of Dental Sleep Medicine, personal fees from Eisenhower Medical Center, personal fees from M. Davis and Company, personal fees from Physician's Seal, personal fees from UC San Diego, personal fees from University of Washington, personal fees from Guy A. Ricciardulli, Attorney at Law, personal fees from Kessinger Law Group PLLC, personal fees from Law Offices Of Robert Hamparyan, personal fees from Law Offices of Rossman, Baumberger, Reboso & Spier, P.A., personal fees from Mcelfish Law Firm, personal fees from Millberg Gordon Stewart PLLC, personal fees from University of Washington, personal fees from Hupy and Abram, SC, personal fees from King & Spalding LLP, personal fees from Law Offices of Power, Rogers & Smith LLP, personal fees from Lewis Brisbois Bisgaard Smith LLP, personal fees from Nurenberg Paris Heller & McCarthy, personal fees from United States Aircraft Insurance Group, personal fees from University of Michigan, personal fees from Zehl and Associates PC, personal fees from Cole, Cole & Easley PC, non-financial support from CurtCo Media Labs LLC, personal fees from Haglund Kelley LLP, personal fees from Marshall Dennehey Warner Coleman Goggin, personal fees from Maryland Sleep Society, personal fees from Morgan & Meyers PLC, personal fees from National Sleep Foundation, personal fees from Nurenberg Paris Heller & McCarthy, personal fees from Ostroff Injury Law PC, personal fees from Pratt Clay LLC, personal fees from Lyon Gorsky Gilbert Livingston LLP, personal fees from Drake Law Firm, personal fees from Segal Law Firm, personal fees from Clement Law Firm, personal fees from Sleep Research Society, personal fees from Tencent, personal fees from Casper Sleep Inc, grants from Dayzz Ltd, grants from Teva Pharma Australia PTY Ltd, outside the submitted work; In addition, Dr. Czeisler has a patent Actiwatch-2 and Actiwatch-Spectrum devices with royalties paid to Philips Respironics Inc.
Funding Information:
This work was supported by awards K01HL150339 , U54MD000538 , K07AG052685 , R01AG056531 , R01AG056031 .
Funding Information:
Dr. Rapoport has received consulting fees from Jazz Pharmaceuticals, Eight Mattress, and Fischer and Paykel Healthcare. Dr. Robbins has received consulting fees from Denihan Hospitality, Rituals Cosmetics, Sleep Cycle, and by Nacht. Dr. Czeisler reports grants from Mary Ann & Stanley Snider via Combined Jewish Philanthropies, grants from National Football League Charities , grants from Optum , grants from Philips Respironics Inc , grants from ResMed Foundation , grants from San Francisco Bar Pilots , other from Schneider Inc , grants from Sysco Corp , grants from Teva Pharmaceuticals Industries Ltd , personal fees from Bose Corporation, non-financial support from Boston Celtics, personal fees from Boston Red Sox, personal fees from Columbia River Bar Pilots, personal fees from Institute of Digital Media and Child Development, personal fees from Klarman Family Foundation, personal fees from Samsung Electronics, personal fees and other from Vanda Pharmaceuticals Inc, personal fees from Zurich Insurance Company Ltd, personal fees from McGraw Hill, other from Cephalon Inc, personal fees from Washington State Board of Pilotage Commissioners, personal fees from Ganésco Inc, grants from Jazz Pharmaceuticals Plc Inc , grants from Regeneron Pharmaceuticals , grants from Sanofi SA , personal fees from New England Journal of Medicine, personal fees from Teva Pharma Australia, personal fees from AARP, personal fees from American Academy of Dental Sleep Medicine, personal fees from Eisenhower Medical Center, personal fees from M. Davis and Company, personal fees from Physician's Seal, personal fees from UC San Diego, personal fees from University of Washington, personal fees from Guy A. Ricciardulli, Attorney at Law, personal fees from Kessinger Law Group PLLC, personal fees from Law Offices Of Robert Hamparyan, personal fees from Law Offices of Rossman, Baumberger, Reboso & Spier, P.A., personal fees from Mcelfish Law Firm, personal fees from Millberg Gordon Stewart PLLC, personal fees from University of Washington, personal fees from Hupy and Abram, SC, personal fees from King & Spalding LLP, personal fees from Law Offices of Power, Rogers & Smith LLP, personal fees from Lewis Brisbois Bisgaard Smith LLP, personal fees from Nurenberg Paris Heller & McCarthy, personal fees from United States Aircraft Insurance Group, personal fees from University of Michigan, personal fees from Zehl and Associates PC, personal fees from Cole, Cole & Easley PC, non-financial support from CurtCo Media Labs LLC, personal fees from Haglund Kelley LLP, personal fees from Marshall Dennehey Warner Coleman Goggin, personal fees from Maryland Sleep Society, personal fees from Morgan & Meyers PLC, personal fees from National Sleep Foundation, personal fees from Nurenberg Paris Heller & McCarthy, personal fees from Ostroff Injury Law PC, personal fees from Pratt Clay LLC, personal fees from Lyon Gorsky Gilbert Livingston LLP, personal fees from Drake Law Firm, personal fees from Segal Law Firm, personal fees from Clement Law Firm, personal fees from Sleep Research Society, personal fees from Tencent, personal fees from Casper Sleep Inc, grants from Dayzz Ltd , grants from Teva Pharma Australia PTY Ltd , outside the submitted work; In addition, Dr. Czeisler has a patent Actiwatch-2 and Actiwatch-Spectrum devices with royalties paid to Philips Respironics Inc.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/3
Y1 - 2021/3
N2 - Background: Sleep difficulties are common among older adults, and clinical management of sleep difficulties commonly includes sleep medication (pharmacological and non-pharmacological). Our research examines sleep medication use and incident dementia over 8 years using nationally representative data from older adults ages 65 years and older in the United States. Methods: We used data collected from the National Health and Aging Trends Study (NHATS), a nationally-representative longitudinal study of Medicare beneficiaries. Routine sleep medication use (pharmacological and non-pharmacological) was defined as use “most nights” or “every night.” Participants were screened for dementia with validated instruments that assessed memory, orientation, and executive function. We conduct prospective analyses to examine the relationship between routine sleep medication use and incident dementia using Cox proportional hazards modeling and estimated survival curves. Analyses controlled for age, sex, marital status, education, and chronic conditions. Results: Among respondents at baseline (n = 6373), most participants (21%) were age 70–74 years of age. Participants were 59% female and the sample comprised non-Hispanic White (71%). At baseline, 15% of our study sample reported using sleep medication routinely, which is representative of 4.6 million older adults in the US. Covariate adjusted proportional hazard models revealed that routinely using sleep medication was associated with incident dementia (HR = 1.30, 95%CI: 1.10 to 1.53, p < 0.01). Conclusions: Our study observed, in a nationally representative study of older adults in the US across 8 years of data that 15% of older adults report routinely using sleep medication, yet routine use of sleeping medication was associated with incident dementia across the follow-up interval. Future research may examine behavioral approaches to improving sleep among older adults.
AB - Background: Sleep difficulties are common among older adults, and clinical management of sleep difficulties commonly includes sleep medication (pharmacological and non-pharmacological). Our research examines sleep medication use and incident dementia over 8 years using nationally representative data from older adults ages 65 years and older in the United States. Methods: We used data collected from the National Health and Aging Trends Study (NHATS), a nationally-representative longitudinal study of Medicare beneficiaries. Routine sleep medication use (pharmacological and non-pharmacological) was defined as use “most nights” or “every night.” Participants were screened for dementia with validated instruments that assessed memory, orientation, and executive function. We conduct prospective analyses to examine the relationship between routine sleep medication use and incident dementia using Cox proportional hazards modeling and estimated survival curves. Analyses controlled for age, sex, marital status, education, and chronic conditions. Results: Among respondents at baseline (n = 6373), most participants (21%) were age 70–74 years of age. Participants were 59% female and the sample comprised non-Hispanic White (71%). At baseline, 15% of our study sample reported using sleep medication routinely, which is representative of 4.6 million older adults in the US. Covariate adjusted proportional hazard models revealed that routinely using sleep medication was associated with incident dementia (HR = 1.30, 95%CI: 1.10 to 1.53, p < 0.01). Conclusions: Our study observed, in a nationally representative study of older adults in the US across 8 years of data that 15% of older adults report routinely using sleep medication, yet routine use of sleeping medication was associated with incident dementia across the follow-up interval. Future research may examine behavioral approaches to improving sleep among older adults.
KW - Dementia
KW - Gerontology
KW - Sleep medication
KW - Sleep medicine
KW - Prospective Studies
KW - Medicare
KW - Humans
KW - Male
KW - United States/epidemiology
KW - Sleep
KW - Dementia/epidemiology
KW - Female
KW - Aged
KW - Longitudinal Studies
UR - http://www.scopus.com/inward/record.url?scp=85097104037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097104037&partnerID=8YFLogxK
U2 - 10.1016/j.sleep.2020.11.004
DO - 10.1016/j.sleep.2020.11.004
M3 - Article
C2 - 33248901
AN - SCOPUS:85097104037
VL - 79
SP - 183
EP - 189
JO - Sleep Medicine
JF - Sleep Medicine
SN - 1389-9457
ER -